NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $16.80 +0.42 (+2.56%) Closing price 04:00 PM EasternExtended Trading$16.81 +0.01 (+0.04%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Greenwich LifeSciences Stock (NASDAQ:GLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$15.96▼$17.4250-Day Range$12.77▼$24.0652-Week Range$7.78▼$34.10Volume116,466 shsAverage Volume235,752 shsMarket Capitalization$246.62 millionP/E RatioN/ADividend YieldN/APrice Target$57.00Consensus RatingHold Company Overview Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies. Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs. Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.AI Generated. May Contain Errors. Read More Greenwich LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreGLSI MarketRank™: Greenwich LifeSciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 325th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingGreenwich LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialGreenwich LifeSciences has a consensus price target of $57.00, representing about 239.3% upside from its current price of $16.80.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 2 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Greenwich LifeSciences are expected to grow in the coming year, from ($1.38) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 560.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.64% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 7.18.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 5.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.41 News SentimentGreenwich LifeSciences has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Greenwich LifeSciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $76,618.00 in company stock, which represents 0.0311% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $76,618.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.47% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLSI Stock News HeadlinesGreenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027August 10, 2026 | quiverquant.comQGreenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027August 10, 2026 | globenewswire.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 14 at 1:00 AM | Porter & Company (Ad)Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 1,500 SharesJuly 30, 2026 | insidertrades.comGreenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 1,100 Shares of StockJuly 29, 2026 | insidertrades.comGreenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22, 2026 | quiverquant.comQGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22, 2026 | globenewswire.comGreenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial OutlookJuly 20, 2026 | quiverquant.comQSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $21.01 at the start of the year. Since then, GLSI stock has decreased by 20.0% and is now trading at $16.80. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) issued its earnings results on Tuesday, August, 11th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.06. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $8 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,260,870 shares at a price of $5.75-$6.75 per share. Aegis Capital served as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional investors include BlackRock Inc. (3.31%), Bank of New York Mellon Corp (0.33%), GSA Capital Partners LLP (0.13%) and Deutsche Bank AG (0.04%). Insiders that own company stock include Snehal Patel and Jaye Thompson. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Greenwich LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/11/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 3 weeks, GLSI's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GLSI CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year Founded2006Price Target and Rating Average Price Target for Greenwich LifeSciences$57.00 High Price Target$69.00 Low Price Target$45.00 Potential Upside/Downside+239.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-833.03% Return on Assets-317.44% Debt Debt-to-Equity RatioN/A Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book560.00Miscellaneous Outstanding Shares14,680,000Free Float7,123,000Market Cap$246.62 million OptionableNot Optionable Beta1.46 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:GLSI) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
